Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 23 |
| Active Pipeline (Recruiting Now) | 16 (6) |
| Completed vs Stopped Early | 4 / 2 (8.7%) |
| Median Closed Actual Enrollment | 63 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hospital Universitario 12 de Octubre | Madrid | 9 |
| Hospital Universitario de Salamanca | Salamanca | 7 |
| Hospital Universitari i Politecnic La Fe | Valencia | 7 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07478991 | Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) | Phase III | RECRUITING |
| NCT05558319 | NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide | Phase III | RECRUITING |
| NCT06544785 | Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase II | RECRUITING |
| NCT07507760 | Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients | Phase II | RECRUITING |
| NCT04090736 | Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemothe | Phase III | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the PETHEMA Foundation Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.